D. Wong, F. Bymaster, D. Mayle, L. Reid, J. Krushinski et al., LY248686, A New Inhibitor of Serotonin and Norepinephrine Uptake, Neuropsychopharmacology, vol.8, issue.1, pp.23-33, 1993.
DOI : 10.1038/npp.1993.4

B. Falissard, M. Lothgren, D. Perahia, and A. Garcia-cebrian, Meta-analyses of duloxetine in the treatment of MDD [Poster]. presented at the 4th International Forum on Mood and Anxiety Disorders : abstract PO13, 2003.

J. Greist, R. Mcnamara, C. Mallinckrodt, J. Rayamajhi, and J. Raskin, Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine, Clinical Therapeutics, vol.26, issue.9, pp.1446-1455, 2004.
DOI : 10.1016/j.clinthera.2004.09.010

S. Brannan, C. Mallinckrodt, E. Brown, M. Wohlreich, J. Watkin et al., Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder, Journal of Psychiatric Research, vol.39, issue.1, pp.43-53, 2005.
DOI : 10.1016/j.jpsychires.2004.04.011

M. Edwardes and M. Baltzan, The generalization of the odds ratio, risk ratio and risk difference tor ???k tables, Statistics in Medicine, vol.14, issue.14, pp.1901-1914, 2000.
DOI : 10.1002/1097-0258(20000730)19:14<1901::AID-SIM514>3.0.CO;2-V

A. Glenny, D. Altman, F. Song, C. Sakarovitch, J. Deeks et al., Indirect comparisons of competing interventions, Health Technology Assessment, vol.9, issue.26, p.9, 2005.
DOI : 10.3310/hta9260

H. Van-houwelingen, L. Arends, and T. Stijnen, Advanced methods in meta-analysis: multivariate approach and meta-regression, Statistics in Medicine, vol.14, issue.4, pp.589-624, 2002.
DOI : 10.1002/sim.1040

A. Andorn, C. Mallinckrodt, J. Watkin, and M. Wohlreich, Efficacy of duloxetine in patients with mild, moderate, or severe depressive symptoms, Poster]. presented at the 158th Annual Meeting of the American Psychiatric Association. Abstract NR363, 2005.

D. Goldstein, C. Mallinckrodt, Y. Lu, and M. Demitrack, Duloxetine in the Treatment of Major Depressive Disorder, The Journal of Clinical Psychiatry, vol.63, issue.3, pp.225-231, 2002.
DOI : 10.4088/JCP.v63n0309

M. Detke, Y. Lu, D. Goldstein, J. Hayes, and M. Demitrack, Duloxetine, 60 mg Once Daily, for Major Depressive Disorder, The Journal of Clinical Psychiatry, vol.63, issue.4, pp.308-315, 2002.
DOI : 10.4088/JCP.v63n0407

M. Detke, Y. Lu, D. Goldstein, R. Mcnamara, and M. Demitrack, Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression, Journal of Psychiatric Research, vol.36, issue.6, pp.383-390, 2002.
DOI : 10.1016/S0022-3956(02)00060-2

M. Detke, C. Wiltse, C. Mallinckrodt, R. Mcnamara, and M. Demitrack, Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial, European Neuropsychopharmacology, vol.14, issue.6, pp.457-470, 2004.
DOI : 10.1016/j.euroneuro.2004.01.002

D. Goldstein, Y. Lu, M. Detke, C. Wiltse, C. Mallinckrodt et al., Duloxetine in the Treatment of Depression, Journal of Clinical Psychopharmacology, vol.24, issue.4, pp.389-399, 2004.
DOI : 10.1097/01.jcp.0000132448.65972.d9

L. Fabre and L. Crismon, Efficacy of fluoxetine in outpatients with major depression, Curr Ther Res, vol.37, pp.115-123, 1985.

P. Stark and C. Hardison, A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder, J Clin Psychiatry, vol.46, pp.53-58, 1985.

J. Cohn and C. Wilcox, A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder, J Clin Psychiatry, vol.46, pp.26-31, 1985.

R. Fieve, P. Goodnick, E. Peselow, and A. Schlegel, Fluoxetine Response: Endpoint vs Pattern Analysis, International Clinical Psychopharmacology, vol.1, issue.4, pp.320-323, 1986.
DOI : 10.1097/00004850-198610000-00006

K. Rickels, J. Amsterdam, and M. Avallone, Fluoxetine in major depression : a controlled study, Curr Ther Res, vol.39, pp.559-563, 1986.

P. Goodnick, R. Fieve, E. Peselow, F. Barouche, and A. Schlegel, Doubleblind treatment of major depression with fluoxetine: use of pattern analysis and relation of HAM-D score to CGI change, Psychopharmacol Bull, vol.23, pp.162-163, 1987.

J. Wernicke, S. Dunlop, B. Dornseif, and R. Zerbe, Fixed-dose fluoxetine therapy for depression, Psychopharmacol Bull, vol.23, pp.164-168, 1987.

L. Fabre, H. Putman, and . Iii, A fixed-dose clinical trial of fluoxetine in outpatients with major depression, J Clin Psychiatry, vol.48, pp.406-408, 1987.

J. Wernicke, S. Dunlop, B. Dornseif, J. Bosomworth, and H. M. , Low-dose fluoxetine therapy for depression, Psychopharmacol Bull, vol.24, pp.183-188, 1988.

N. Harto, K. Spera, and R. Branconnier, Fluoxetine-induced reduction of body mass in patients with major depressive disorder, Psychopharmacol Bull, vol.24, pp.220-223, 1988.

W. Byerley, F. Reimherr, D. Wood, and B. Grosser, Fluoxetine, a Selective Serotonin Uptake Inhibitor, for the Treatment of Outpatients with Major Depression, Journal of Clinical Psychopharmacology, vol.8, issue.2, pp.112-115, 1988.
DOI : 10.1097/00004714-198804000-00005

M. Muijen, D. Roy, T. Silverstone, A. Mehmet, and M. Christie, A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients, Acta Psychiatrica Scandinavica, vol.19, issue.1, pp.384-390, 1988.
DOI : 10.1007/BF00177927

J. Feighner, W. Boyer, C. Merideth, and G. Hendrickson, A Double-Blind Comparison of Fluoxetine, Imipramine and Placebo in Outpatients with Major Depression, International Clinical Psychopharmacology, vol.4, issue.2, pp.127-134, 1989.
DOI : 10.1097/00004850-198904000-00004

S. Dunlop, B. Dornseif, J. Wernicke, and J. Potvin, Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression, Psychopharmacol Bull, vol.26, pp.173-180, 1990.

M. Valducci, A. Valducci, C. Paoletti, and C. Colonna, A double-blind, placebo controlled clinical trial to evaluate efficacy and safety of fluoxetine in the treatment of major depression, G Ital Ric Clin Ther, vol.13, pp.59-64, 1992.

J. Heiligenstein, G. Tollefson, and D. Faries, Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo, Journal of Affective Disorders, vol.30, issue.3, pp.163-173, 1994.
DOI : 10.1016/0165-0327(94)90077-9

J. Sramek, K. Kashkin, O. Jasinsky, D. Kardatzke, S. Kennedy et al., Placebo-controlled study of ABT-200 versus fluoxetine in the treatment of major depressive disorder, Depression, vol.4, issue.4, pp.199-203, 1995.
DOI : 10.1002/depr.3050030407

M. Fava, J. Amsterdam, J. Deltito, C. Salzman, M. Schwaller et al., A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo in Outpatients with Major Depression, Annals of Clinical Psychiatry, vol.10, issue.4, pp.145-150, 1998.
DOI : 10.3109/10401239809147030

R. Rudolph and A. Feiger, A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression, Journal of Affective Disorders, vol.56, issue.2-3, pp.171-181, 1999.
DOI : 10.1016/S0165-0327(99)00067-1

M. Corrigan, A. Denahan, C. Wright, R. Ragual, and D. Evans, Comparison of pramipexole, fluoxetine, and placebo in patients with major depression, Depression and Anxiety, vol.115, issue.2, pp.58-65, 2000.
DOI : 10.1002/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H

C. Coleman, B. King, C. Bolden-watson, M. Book, R. Segraves et al., A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine, Clinical Therapeutics, vol.23, issue.7, pp.1040-1058, 2001.
DOI : 10.1016/S0149-2918(01)80090-4

A. Khan, L. Fabre, and R. Rudolph, Venlafaxine in depressed outpatients, Psychopharmacol Bull, vol.27, pp.141-144, 1991.

E. Schweizer, C. Weise, C. Clary, I. Fox, and K. Rickels, Placebo-Controlled Trial of Venlafaxine for the Treatment of Major Depression, Journal of Clinical Psychopharmacology, vol.11, issue.4, pp.233-236, 1991.
DOI : 10.1097/00004714-199108000-00002

L. Cunningham, R. Borison, J. Carman, G. Chouinard, J. Crowder et al., A comparison of venlafaxine, trazodone, and placebo in major depression [published erratum appears, J Clin Psychopharmacol, vol.14, issue.4, p.292, 1994.

E. Schweizer, J. Feighner, L. Mandos, and K. Rickels, Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients, J Clin Psychiatry, vol.55, pp.104-108, 1994.

L. Cunningham, Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients with Major Depression, Annals of Clinical Psychiatry, vol.9, issue.3, pp.157-164, 1997.
DOI : 10.3109/10401239709147791

M. Thase, Efficacy and Tolerability of Once-Daily Venlafaxine Extended Release (XR) in Outpatients With Major Depression, The Journal of Clinical Psychiatry, vol.58, issue.9, pp.393-398, 1997.
DOI : 10.4088/JCP.v58n0904

P. Silverstone and A. Ravindran, Once-Daily Venlafaxine Extended Release (XR) Compared With Fluoxetine in Outpatients With Depression and Anxiety, The Journal of Clinical Psychiatry, vol.60, issue.1, pp.22-28, 1999.
DOI : 10.4088/JCP.v60n0105

L. Sauriol, M. Laporta, M. Edwardes, M. Deslandes, R. N. Suissa et al., Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach, Clinical Therapeutics, vol.23, issue.6, pp.942-956, 2001.
DOI : 10.1016/S0149-2918(01)80082-5

F. Song, D. Altman, A. Glenny, and J. Deeks, Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses, BMJ, vol.326, issue.7387, p.472, 2003.
DOI : 10.1136/bmj.326.7387.472

P. Vis, M. Van-baardewijk, and T. Einarson, PMH44 DULOXETINE AND VENLAFAXINE-XR IN THE TREATMENT OF MDD: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS, Value in Health, vol.8, issue.6, pp.391798-807, 2005.
DOI : 10.1016/S1098-3015(10)67790-X

R. Hansen, G. Gartlehner, K. Lohr, B. Gaynes, and T. Carey, Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder, Annals of Internal Medicine, vol.143, issue.6, pp.415-426, 2005.
DOI : 10.7326/0003-4819-143-6-200509200-00006

P. Bech, P. Ciadella, M. Haugh, M. Birkett, A. Hours et al., Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression, The British Journal of Psychiatry, vol.176, issue.5, pp.421-428, 2000.
DOI : 10.1192/bjp.176.5.421

R. Greenberg, R. Bornstein, M. Zborowski, S. Fisher, and M. Greenberg, A meta-analysis of fluoxetine outcome in the Treatment of depression. The journal of Nervous and Mental Disease, pp.547-551, 1994.

F. Song, A. Glenny, and D. Altman, Indirect Comparison in Evaluating Relative Efficacy Illustrated by Antimicrobial Prophylaxis in Colorectal Surgery, Controlled Clinical Trials, vol.21, issue.5, pp.488-497, 2000.
DOI : 10.1016/S0197-2456(00)00055-6

F. Mcalister, A. Laupacis, G. Wells, and D. Sackett, Users' Guides to the Medical Literature, JAMA, vol.282, issue.14, pp.1371-1377, 1999.
DOI : 10.1001/jama.282.14.1371

M. Egger, S. Davey, M. Schneider, and C. Minder, Bias in meta-analysis detected by a simple, graphical test, BMJ, vol.315, issue.7109, pp.629-634, 1997.
DOI : 10.1136/bmj.315.7109.629

J. Geddes, N. Freemantle, P. Harrison, and P. Bebbington, Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis, BMJ, vol.321, issue.7273, pp.1371-1376, 2000.
DOI : 10.1136/bmj.321.7273.1371